Ochre Bio develops genomic medicines to rejuvenate fatty donor livers before transplant, so that everyone who needs a new liver gets one.
Location: United Kingdom, England, Oxford
Employees: 11-50
Total raised: $39.6M
Founded date: 2019
Investors 8
| Date | Name | Website |
| - | Pathway Bi... | pathwaybio... |
| 17.04.2022 | Khosla Ven... | khoslavent... |
| - | Expa | expa.com |
| 05.02.2022 | Y Combinat... | ycombinato... |
| - | Norrsken V... | norrsken.v... |
| 14.01.2022 | Thomas McI... | tgm.com |
| 24.02.2022 | Lifeforce ... | lifeforcec... |
| - | Bioverge | ventures.b... |
Funding Rounds 2
| Date | Series | Amount | Investors |
| 21.10.2022 | Series A | $30M | - |
| 21.06.2021 | Seed | $9.6M | Khosla Ven... |
Mentions in press and media 11
| Date | Title | Description |
| 26.07.2024 | Leading innovation: 10 promising European startups focusing on biopharmaceuticals | Biopharmaceuticals, often known as bio-pharma, represent a dynamic sector within the pharmaceutical industry that uses biological processes to develop drugs and therapies. Unlike traditional pharmaceuticals, which are typically synthesized ... |
| 21.10.2022 | Ochre Bio closes €30M Series A funding round | EIT Health-supported Ochre Bio has closed a Series A funding round of €30M. As a participant of our Gold Track accelerator programme, we have contributed €500K to support their development. In 2019, chronic liver disease was the cause of o... |
| 10.10.2022 | RNA therapies startup Ochre Bio lands $30M to take on chronic liver disease | Ochre Bio co-founders Quin Wills, chief scientific officer (left), and Jack O’Meara, CEO (right). Photo by Business Wire. A biotech startup developing RNA therapies for liver disease by running tests in live human livers has raised $30 mill... |
| 20.07.2021 | Calling all UK tech firms: UK government’s new €434.6M scheme to help scale-up innovations opens for applications | Today, the new £375M (approx €434.68M) Future Fund: Breakthrough — announced by the Chancellor of the Exchequer at Budget 2021, opens today for applications. This UK-wide programme will deliver £375M of government funding via British Patien... |
| 21.06.2021 | Ochre Bio Raises $9.6M in Seed Financing | Ochre Bio, an Oxford, England, UK-based biotech company developing RNA medicines for chronic liver diseases, closed a $9.6M seed financing. The round was led by Khosla Ventures, with participation from Backed VC, Apollo Health Ventures, Sel... |
| 16.06.2021 | In private equity, compensation lags for women in senior positions | This is the web version of Term Sheet, a daily newsletter on the biggest deals and dealmakers. Sign up to get it delivered free to your inbox. In general, 2020 proved to be a good year for private equity dealmakers. Even as deal value and v... |
| 16.06.2021 | Ochre Bio : Closes $9.6M Seed Financing Led by Khosla Ventures | Ochre Bio, a biotech company developing RNA medicines for chronic liver diseases, today announced the closing of a $9.6M seed financing round led by Khosla Ventures, with participation from Backed VC, Apollo Health Ventures, Selvedge, Hoxto... |
| 16.06.2021 | In private equity, compensation lags for women in senior positions | This is the web version of Term Sheet, a daily newsletter on the biggest deals and dealmakers. Sign up to get it delivered free to your inbox. Paid Content 4 ways CEOs can build a successful cloud strategy From PwC In general, 2020 proved t... |
| 17.03.2020 | All the companies from Y Combinator’s W20 Demo Day, Part IV: Healthcare, Biotech, Fintech and Nonprofits | Y Combinator’s Demo Day was a bit different this time around. As concerns grew over the spread of COVID-19, Y Combinator shifted the event format away from the two-day gathering in San Francisco we’ve gotten used to, instead opting to have ... |
| - | Ochre Bio | “Ochre Bio is developing therapies for the biggest liver health challenges.” |
Show more